Soligenix (NSDQ:SNGX) skyrocketed up 89% in premarket trading this morning after announcing today that it entered into an exclusive worldwide licensing agreement with Boston Scientific (NYSE:BSX) for its CoVaccine HT novel vaccine adjuvant for COVID-19.
Shares of SNGX were up 12.5% at $1.58 per share in mid-morning trading today as well.
Boston Scientific’s BTG Specialty Pharmaceuticals division’s CoVaccine HT is now licensed to Princeton, N.J.-based Soligenix for the fields of SARS-CoV-2, the virus causing COVID-19. The agreement was executed between Soligenix and Protherics Medicines Development. Terms of the deal are not being disclosed.